Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF). [More]
Rotavirus vaccine program reduces hospitalization rates by more than 70% in Ontario

Rotavirus vaccine program reduces hospitalization rates by more than 70% in Ontario

Hospitalization for rotavirus infections decreased by > 70% following the introduction of a vaccine program in Ontario, Canada, according to a study published May 11, 2016 in the open-access journal PLOS ONE by Sarah Wilson from Public Health Ontario and the Institute for Clinical Evaluative Sciences, Canada, and colleagues. [More]
UAB hospital leads the way in improving antibiotic use

UAB hospital leads the way in improving antibiotic use

One of today's urgent health threats is antibiotic resistance, caused by inappropriate prescription and use of antibiotics, and — according to the Centers for Disease Control and Prevention — approximately 50 percent of all antibiotics prescribed in the United States are unnecessary or inappropriate, with many of them prescribed in inpatient settings. [More]
Common misconception about penicillin allergies

Common misconception about penicillin allergies

It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was your parents who said so. According to a Texas A&M Health Science Center allergist, many people who believe they're allergic to this antibiotic may not actually be allergic at all. [More]
Children infected with Cryptosporidium parasite more likely to suffer from stunted growth

Children infected with Cryptosporidium parasite more likely to suffer from stunted growth

Children infected even just once with a certain type of waterborne parasite are nearly three times as likely to suffer from moderate or severe stunted growth by the age of two than those who are not - regardless of whether their infection made them feel sick, new Johns Hopkins Bloomberg School of Public Health-led research suggests. [More]
ITJ researchers develop new hydrating beverage for athletes

ITJ researchers develop new hydrating beverage for athletes

Jiquiquilpan's Institute of Technology in Mexico developed a hydrating beverage for athletes that is based on agave's fructans, that not only supplies the adequate water levels to the organisms, but also offers other benefits such as dietetic fiber. [More]
Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]

High doses of Imodium to self-treat opioid addictions could be extremely dangerous

The over-the-counter anti-diarrhea medication Imodium, or its key ingredient loperamide, is increasingly being abused by people attempting to self-treat their opioid addiction, with sometime fatal results. [More]
Study shows syringe-like device acts as traffic cop directing bacteria to carry out infection

Study shows syringe-like device acts as traffic cop directing bacteria to carry out infection

A study has found that a syringe-like device used to invade intestinal cells also acts as a traffic cop -- directing bacteria where to go and thereby enabling them to efficiently carry out infection. [More]
Flu vaccinations for pregnant women reduce newborn’s influenza risk during first six months of life

Flu vaccinations for pregnant women reduce newborn’s influenza risk during first six months of life

Babies whose moms get flu vaccinations while pregnant have a significantly reduced risk of acquiring influenza during their first six months of life, a new study shows, leading the authors to declare that the need for getting more pregnant women immunized is a public health priority. [More]
UGA researcher works to advance effective treatment for infectious mononucleosis

UGA researcher works to advance effective treatment for infectious mononucleosis

The University of Georgia's Mark Ebell wasn't impressed with research on infectious mononucleosis when he wrote his first published review on it back in the 1990s. He still isn't—a subject he discusses in the April issue of the Journal of the American Medical Association. [More]
Antibiotic treatment may allow bad bugs to flourish

Antibiotic treatment may allow bad bugs to flourish

Antibiotics are essential for fighting bacterial infection, but, paradoxically, they can also make the body more prone to infection and diarrhea. [More]
Half-strength apple juice followed by preferred fluid choice better for treating kids with mild gastroenteritis

Half-strength apple juice followed by preferred fluid choice better for treating kids with mild gastroenteritis

Children with mild gastroenteritis and minimal dehydration experienced fewer treatment failures such as IV rehydration or hospitalization when offered half-strength apple juice followed by their preferred fluid choice compared with children who received electrolyte maintenance solution to replace fluid losses, according to a study published online by JAMA. The study is being released to coincide with its presentation at the Pediatric Academic Societies meeting. [More]
CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

Cellular and Molecular Gastroenterology and Hepatology is committed to publishing impactful digestive biology research covering a broad spectrum of themes in GI, hepatology and pancreatology. We wanted to share two new CMGH articles, which both offer important insight into future interventions for chronic conditions. [More]
Outbreak of tropical parasitic infection observed for first time in the Arctic

Outbreak of tropical parasitic infection observed for first time in the Arctic

An outbreak of an intestinal parasite common in the tropics, known as Cryptosporidium, has been identified for the first time in the Arctic. The discovery was made in Nunavik, Quebec, by a team from the Research Institute of the McGill University Health Centre, in collaboration with the Nunavik Department of Public Health, Institut National de Santé Publique du Québec and Health Canada. The discovery, which was documented in the journal PLoS Neglected Tropical Diseases, could have long-term implications for the health of children in Nunavik and Nunavut's communities. [More]
Research highlights global economic burden of norovirus

Research highlights global economic burden of norovirus

While norovirus is often linked in the news to outbreaks on cruise ships, the highly contagious stomach bug sickens nearly 700 million around the world every year and results in roughly $4.2 billion in health care costs and $60.3 billion in societal costs annually, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
TNF-alpha protein involved in autoimmune diseases may also promote tissue healing

TNF-alpha protein involved in autoimmune diseases may also promote tissue healing

As its name suggests, inflammatory bowel disease, which afflicts more than 1.6 million Americans, involves chronic inflammation of all or some of the digestive tract. An autoimmune disease known to have a strong genetic component, its symptoms are abdominal cramps, bloody diarrhea, and fever and, sometimes, weight loss. IBD, which is a group of inflammatory conditions, includes Crohn's disease and ulcerative colitis. [More]
Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer. [More]
Taking antibiotics in early childhood can disrupt immune system function lifelong

Taking antibiotics in early childhood can disrupt immune system function lifelong

Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong. [More]
Advertisement